IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases
, Moustafa Moustafa-Oglou 1, Karin Teppert 1, Ilona Hagelstein 2,3, Joseph Kauer 1,2, Martin Pflügler 1,2,3, Kristina Neumann 1, Hans-Georg Rammensee 1,3, Thomas Metz 4, Andreas Herrmann 5, Helmut R. Salih 2,3, Gundram Jung 1,3 and Latifa Zekri 1,2,3,*
Round 1
Reviewer 1 Report
This manuscript is well-written, and the topic is interesting.
1. Did you analyze other cytokines (IL-2, IL-4, TNF-alpha, interferon-r, and TGF-b) after treatment of anti-CD95 bispecific antibodies? what about the effect on T cells? ( T cells also express CD95).
2. IL-10 is known to be released by regulatory B cells. Do you think that this is a bystander effect?
3. Did you compare the anti-tumor effect of the anti-CD20-CD95 bispecific antibody with rituximab in vitro and in vivo?
4. Do you have a PK-data comparing with FabSc?
5. what about in vitro cytotoxicities of these anti-CD19-CD95 and anti-CD20-CD95 bispecific antibodies compared with the corresponding FabSc?
6. Did you test the anti-tumor efficacy of these CD95 bispecific antibodies with other representative leukemia or lymphoma cell lines?
7. Do you have in vivo data of anti-CD19-CD95 bispecific antibody?
Author Response
Please see the attachment
Author Response File: 
Author Response.docx
Reviewer 2 Report
The authors summarize development of two antibodies in the IgGsc format targeting the B cell-restricted antigens CD20 and CD19 for target cell-mediated induction of apoptosis Overall the article is interesting, well-written and is worthy of publishing in Cancers.
The only other modifications I see as appropriate would be a) long-term stability of this BiAbs b) PK study results of this BisAbs c) a semi-quantitative assessment of developability and scalability of this mAb production.
Author Response
Please see the attachment.
Author Response File: Author Response.docx
